Stephanie Saw, Medical Oncologist at National Cancer Center of Singapore, shared on X:
“How far have we come treating EGFRm NSCLC and what new dilemmas do we face?
We discuss biomarkers, rationalising options and challenging clinical scenarios. Always a pleasure to write with friends.”
Title: Targeting Classical EGFR Mutations in Lung Cancer: Twenty Years of Progress and Beyond
Authors: Yuji Uehara, Hiroto Hatano, Jia-Tao Zhang, Jiefei Han, Kevin L. M. Chua, Stephanie P. L. Saw
You can also read:
INTEGRAL-Risk May Refine Lung Cancer Screening Eligibility
